SM
PCRX icon

Sabby Management’s Pacira BioSciences PCRX Stock Holding History

Sabby Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,390
Closed -$209K – 197
2017
Q2 		$209K Buy
+4,390
New +$204K 0.01% 177
2015
Q4 		– Sell
-31,100
Closed -$1.76M – 355
2015
Q3 		$1.28M Buy
+31,100
New +$1.9M 0.05% 209

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Sabby Management's PCRX Position: Q3 2017 in Review

Sabby Management sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 4,390 shares — an estimated $209K sold.

Sabby Management first reported a position in PCRX in Q3 2015 and held it in 2 quarters. The position peaked at $1.28M in Q3 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • Sabby Management reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 4,390 Pacira BioSciences shares in Q3 2017, an estimated $209K.
  • Sabby Management first reported a position in Pacira BioSciences in Q3 2015 and held it in 2 quarters.
  • Sabby Management's Pacira BioSciences position peaked at $1.28M in Q3 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.